NCT06715215 Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia
| NCT ID | NCT06715215 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sohag University |
| Condition | Immune Thrombocytopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-11-15 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Immune thrombocytopenia (ITP) are antibody-mediated disorders in which platelets are destroyed mainly through activating immunoglobulin (IgG) Fc receptors on phagocytes in the spleen and liver, eventually resulting in thrombocytopenia Acute phase proteins (APP) are inflammation markers that exhibit significant changes in serum concentration during inflammation. These are also important mediators produced in the liver during acute and chronic inflammatory states. Acute phase reactants can be classified as positive or negative, depending on their serum concentrations during inflammation. Positive acute phase reactants are upregulated, and their concentrations increase during inflammation. Negative acute phase reactants are downregulated, and their concentrations decrease during inflammation. Positive acute phase proteins include procalcitonin, C-reactive protein, ferritin, fibrinogen, hepcidin, and serum amyloid A. Negative acute phase reactants include albumin, prealbumin, transferrin, retinol-binding protein, and antithrombin CRP is now well established as a major acute phase protein and is used in daily clinical practice as a sensitive biomarker for infection and inflammation, with its level increasing from \<0.05 to \>500 mg/L after acute infections. CRP is produced by hepatocytes, in response to inflammatory cytokines such as interleukin (IL)-6 and IL-1, with serum concentrations rising to \>5 mg/L after 6 hours and peaking after ∼48 hours. In healthy young adult volunteer blood donors, the median concentration of CRP was found to be ∼0.8 mg/L CRP levels are useful as a clinical diagnostic tool for infection, and it is a common knowledge that ITP is triggered by viral infection that precedes the clinical picture of ITP by a few days to a few weeks Procalcitonin (PCT) is used as a reliable inflammatory biomarker with high sensitivity and specificity ferritin was confirmed as an inflammation and infection biomarker in the diagnosis of viral and bacterial infections.
Eligibility Criteria
Inclusion Criteria: * Patients with platelet less than 100 × 109/L diagnosed as immune thrombocytopenia by bone marrow findings . Age of patients : from 1 year to 50 years. Exclusion Criteria: * \- Other causes of thrombocytopenia as: * Hypersplenism. * Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes. * Cancer treatments like chemotherapy and radiation therapy. * Exposure to toxic chemicals as arsenic and benzene. * Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06715215 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 50 Years, studying Immune Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06715215 currently recruiting?
Yes, NCT06715215 is actively recruiting participants. Contact the research team at rana_mohamed_post@med.sohag.edu.eg for enrollment information.
Where is the NCT06715215 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT06715215 clinical trial?
NCT06715215 is sponsored by Sohag University. The trial plans to enroll 100 participants.